openPR Logo
Press release

Primary Sclerosing Cholangitis Market to Exhibit Growth at a CAGR of X% by 2032, estimates DelveInsight

04-25-2024 02:16 AM CET | Health & Medicine

Press release from: ABNewswire

Primary Sclerosing Cholangitis Market to Exhibit Growth at

DelveInsight's 'Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the Primary Sclerosing Cholangitis, historical and forecasted epidemiology as well as the market trends in the United States, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan.

Key Takeaways from the Primary Sclerosing Cholangitis Market Report

* The increase in Primary Sclerosing Cholangitis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
* As per DelveInsight analysis, the Primary Sclerosing Cholangitis Market is anticipated to witness growth at a considerable CAGR.
* The leading Primary Sclerosing Cholangitis Companies working in the market include Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
* Promising Primary Sclerosing Cholangitis Therapies in the various stages of development include Ritivixibat, Cenicriviroc 150 mg, HK-660S, Elafibranor 80 mg, Volixibat, PLN-74809, and others.
* April 2024:- Pliant Therapeutics Inc.- A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC). A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis.
* April 2024:-Mirum Pharmaceuticals Inc.- A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis. The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

Discover which therapies are expected to grab the Primary Sclerosing Cholangitis Market Share @ Primary Sclerosing Cholangitis Market Outlook [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Primary Sclerosing Cholangitis Overview

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation and scarring (fibrosis) of the bile ducts inside and outside the liver. Bile ducts are the tubes that carry bile (a digestive fluid produced by the liver) from the liver to the gallbladder and small intestine. In PSC, inflammation and scarring narrow and block the bile ducts, leading to problems with bile flow and causing damage to the liver over time.

Primary Sclerosing Cholangitis Epidemiology Insights

The epidemiology section of Primary Sclerosing Cholangitis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Primary Sclerosing Cholangitis Epidemiology trends @ Primary Sclerosing Cholangitis Epidemiological Insights [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Primary Sclerosing Cholangitis Drugs Market

The Primary Sclerosing Cholangitis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Primary Sclerosing Cholangitis signaling in Primary Sclerosing Cholangitis are likely to uncover new therapeutic targets and further expand treatment options for patients.

Primary Sclerosing Cholangitis Treatment Market Landscape

The Primary Sclerosing Cholangitis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Primary Sclerosing Cholangitis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Primary Sclerosing Cholangitis treatment guidelines, visit @ Primary Sclerosing Cholangitis Treatment Market Landscape [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Primary Sclerosing Cholangitis Market Outlook

The report's outlook on the Primary Sclerosing Cholangitis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Primary Sclerosing Cholangitis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Primary Sclerosing Cholangitis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Primary Sclerosing Cholangitis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Primary Sclerosing Cholangitis Drugs Uptake

The drug chapter of the Primary Sclerosing Cholangitis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Primary Sclerosing Cholangitis.

Major Primary Sclerosing Cholangitis Companies

Several Primary Sclerosing Cholangitis Companies working in the market include Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.

Learn more about the FDA-approved drugs for Primary Sclerosing Cholangitis @ Drugs for Primary Sclerosing Cholangitis Treatment [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Primary Sclerosing Cholangitis Market Research Report

* Coverage- 7MM
* Primary Sclerosing Cholangitis Companies- Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
* Primary Sclerosing Cholangitis Pipeline Therapies- Ritivixibat, Cenicriviroc 150 mg, HK-660S, Elafibranor 80 mg, Volixibat, PLN-74809, and others.
* Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis Market Drivers and Barriers
* Primary Sclerosing Cholangitis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Primary Sclerosing Cholangitis Drugs in development @ Primary Sclerosing Cholangitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Primary Sclerosing Cholangitis (PSC) Market Overview at a Glance

4. Executive Summary of Primary Sclerosing Cholangitis (PSC)

5. Disease Background and Overview

6. Epidemiology and Patient Population

7. Patient Journey

8. Emerging Therapies

10. Primary Sclerosing Cholangitis (PSC): Seven Major Markets + Nordic Countries Market Analysis

11. SWOT Analysis

12. Unmet Needs

13. KOL Views

14. Market Access and Reimbursement

15. Acronyms and Abbreviations

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-sclerosing-cholangitis-market-to-exhibit-growth-at-a-cagr-of-x-by-2032-estimates-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Sclerosing Cholangitis Market to Exhibit Growth at a CAGR of X% by 2032, estimates DelveInsight here

News-ID: 3475573 • Views:

More Releases from ABNewswire

Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repair Services to Support St. Louis Park Homeowners
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold. Responding to a Growing Need for Water Damage Restoration Property owners across Minnesota are increasingly seeking
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Injury Attorneys Representation in Port Jefferson Station
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents. Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washing Prevents Long-Term Damage in Millsboro DE
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces. In
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection. Market Overview: Understanding Tampa Bay Remodeling Investment Trends Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.

All 5 Releases


More Releases for Primary

Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031. Primary Biliary Cholangitis (PBC), formerly known as
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy Email primaryhealthcare@pulsusgathering.org On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5% Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk